10+
Installationen · ≈16
—
0 Bewertungen
2025-03-13
erste Veröffentlichung
2026-02-03
letzte Aktualisierung
Beschreibung
Study for Participants with Resected or Unresectable KRAS G12C-Mutant, NSCLC
This app has been exclusively created for participants with Resected or Unresectable KRAS G12C-Mutant, NSCLC.
It contains Televisit functionality and allows participants to complete questionnaires.
The study is a Phase 3, Multicenter, Double-Blind, Placebo-controlled Study Assessing the Efficacy and Safety of Olomorasib in Combination with Standard of Care Immunotherapy in Participants with Resected or Unresectable KRAS G12C-Mutant, Non-Small Cell Lung Cancer - SUNRAY-02. This app is specifically intended for participants in the J3M-MC-JZQH study only.
(Televisit tasks are not enabled by default and may be enabled as needed, by study officials.)
Neuigkeiten
Bug fixes and performance improvements
Details
| Version | 5.4.1100.1-prod |
|---|---|
| Mindestversion Android | 8.0 |
| Rezensionen | 0 |
| Verfügbar in | Amerikanisch-Samoa, Österreich, Australien, Ålandinseln, Belgien, Bulgarien, St. Barthélemy, Brasilien, Kanada, Schweiz, Chile, China und 53 weitere |
| Entwicklerkontakte | im Business-Tarif |
| Erfasst | 2026-11-15 |
Diese Daten in der API
Der vollständige Eintrag als JSON kostet 1 Token.
curl -H "X-API-Key: YOUR_KEY" \ "https://apkapi.com/api/v1/app?id=com.medable.lilly.jzqh"
